Market Overview

Wedbush Securities Reiterates Outperform Rating, $102 PT on Humana

Share:
Related HUM
Oppenheimer: 3 Healthcare Stocks And 2 Energy Stocks To Buy Now
PE Firm Sets Ventures With Select Medical, Tenet Healthcare
Seeking Alpha's Biotech Weekly: Gilead Cardiac Flap, Ohr Sinks, MEI Selloff, And More (Seeking Alpha)

In a report published Wednesday, Wedbush Securities reiterated its Outperform rating and $102.00 price target on Humana (NYSE: HUM).

Wedbush Securities noted, “Budget headwinds could weigh on the group through year end, but ultimately we believe volume growth outweighs rate risks. The group historically comes under pressure in times of regulatory uncertainty, we view the grand bargain budget scenario as presenting more uncertainty than sequestration, but view both as manageable risks from an operational standpoint. We believe Humana has several levers to pull to maintain 5% margins in the face of rate pressure, but even under a bear-case (an unlikely in our opinion) 3% margin scenario we believe volume growth will more than outweigh the margin compression by 2015.”

Humana closed on Tuesday at $68.29.

Latest Ratings for HUM

DateFirmActionFromTo
Mar 2015BarclaysMaintainsEqual-weight
Jan 2015BarclaysMaintainsEqual-weight
Jan 2015Deutsche BankUpgradesSellHold

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

Around the Web, We're Loving...